Login
Begin your journey
Home › Learn › Medications Compared
Medications Compared

Does Tirzepatide Work Better Than Semaglutide?

A woman reading about her options on her phone

On average, yes — in the only large head-to-head trial of the two branded weight-management products (SURMOUNT-5, which compared Zepbound® directly against Wegovy®), participants on tirzepatide lost roughly 20% of their body weight over 72 weeks versus roughly 14% on semaglutide.[1] That's a real, well-documented difference. But "works better on average" is not the same as "works better for you": tolerability, health history, and cost all shape which medication is the right prescription, and plenty of people do their best on semaglutide. The choice between them is a medical decision your provider makes with you — here's the evidence they're weighing.

Why tirzepatide averages higher: one pathway vs. two

Semaglutide activates the GLP-1 receptor — mimicking a gut hormone that signals fullness to your brain, slows stomach emptying, quiets food cravings, and steadies blood sugar.[2]

Tirzepatide activates the GLP-1 receptor and the GIP receptor.[3] That second pathway appears to add appetite and metabolic effects on top of what GLP-1 activation alone achieves — the leading explanation for the larger average results.

Branded products, for the record: semaglutide is sold as Wegovy® (FDA-approved for chronic weight management)[4] and Ozempic® (FDA-approved to improve glycemic control in type 2 diabetes)[5], both from Novo Nordisk. Tirzepatide is sold as Zepbound® (FDA-approved for chronic weight management)[6] and Mounjaro® (FDA-approved to improve glycemic control in type 2 diabetes)[7], both from Eli Lilly.

The numbers, properly attributed

All figures below come from clinical trials of the brand-name, FDA-approved products — and individual results vary:

  • STEP-1 (Wegovy®): average weight reduction of roughly 15% over 68 weeks, versus ~2% with placebo, alongside diet and activity changes.[8]
  • SURMOUNT-1 (Zepbound®/tirzepatide): up to roughly 21% average reduction over 72 weeks at the highest dose.[9]
  • SURMOUNT-5 (head-to-head, Zepbound® vs. Wegovy®): roughly 20% vs. roughly 14% average reduction over 72 weeks[1] — the cleanest direct comparison available, and it favored tirzepatide.

Note what these numbers are: averages, from long trials, of branded products, in combination with lifestyle change. They are not a guarantee of any individual outcome, and compounded preparations — which are not FDA-approved — were not the products studied.

Where the comparison gets more even

Side effects. Both medications share the same core profile — nausea, diarrhea, constipation, vomiting, mostly early and mostly easing with time.[2][3] Neither is reliably "gentler"; individual tolerance differs more than the molecules do. Some people who struggle on one do fine on the other, in either direction.

Response is individual. Every trial average contains strong responders and modest responders on both medications. A person's response to semaglutide doesn't predictably map onto what tirzepatide would have done for them, and vice versa.

Cost. Tirzepatide is the more expensive molecule. Through Ladies First, plans with compounded semaglutide start at $219 per 28 days of medication on a 12-week plan ($249 flexible); compounded tirzepatide runs $309 per 28 days on a 12-week plan ($339 flexible); oral semaglutide is $279. Compounded preparations contain the same active ingredients as the branded products but are not FDA-approved — a distinction we keep explicit. Brand-name options are also available through your provider. Over a year-plus of treatment, that price gap is a legitimate factor, and your provider treats it as one.

History and track record. Semaglutide has the longer track record: its first brand, Ozempic®, was FDA-approved in December 2017,[10] while tirzepatide (Mounjaro®) was FDA-approved in May 2022,[3] which some people and providers weigh in semaglutide's favor.

How a provider actually chooses

During intake, a licensed provider looks at your full picture: how much weight matters medically for you, conditions like insulin resistance or PCOS, medication history (including any prior GLP-1 experience), tolerability risk, and what's sustainable for your budget — because the medication you can stay on beats the medication with the better average. Sometimes the answer is start with semaglutide and reassess; sometimes it's tirzepatide first; sometimes it's a switch later (Can You Switch from Semaglutide to Tirzepatide?).

The bottom line

Tirzepatide outperformed semaglutide on average in the head-to-head trial of the branded products — that part isn't controversial. But averages don't take medications; you do. The right prescription is the one matched to your health history, your tolerance, and your real life, and that's a determination a licensed medical provider makes during intake — not a ranking you pick from.

Get the recommendation that fits you. Answer a few health questions online — about 3 minutes, free — and a medical provider licensed in your state reviews your history and recommends the appropriate medication, usually within 48 hours. You're never charged unless a provider approves your plan.

See If You Qualify →

Sources

  1. SURMOUNT-5 — "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." N Engl J Med 2025;393(1):26-36. pubmed.ncbi.nlm.nih.gov/40353578
  2. Semaglutide — StatPearls, NCBI Bookshelf. ncbi.nlm.nih.gov/books/NBK603723
  3. Tirzepatide — StatPearls, NCBI Bookshelf. ncbi.nlm.nih.gov/books/NBK585056
  4. Wegovy® (semaglutide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov
  5. Ozempic® (semaglutide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov
  6. Zepbound® (tirzepatide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov
  7. Mounjaro® (tirzepatide) Prescribing Information — DailyMed. dailymed.nlm.nih.gov
  8. STEP-1 — semaglutide 2.4 mg once weekly in adults with overweight or obesity. N Engl J Med 2021. pubmed.ncbi.nlm.nih.gov/33567185
  9. SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022. pubmed.ncbi.nlm.nih.gov/35658024
  10. Drugs@FDA: Ozempic® (NDA 209637), original FDA approval December 5, 2017. accessdata.fda.gov
The honest close every article here gets: whether any medication is appropriate for you is a medical decision, made by a medical provider licensed in your state after reviewing your actual health history — not by an article. Finding out takes about 3 minutes, costs nothing, and you’re never charged unless a provider approves your plan.
See If You Qualify

Free 3-minute check · No payment until approval · 100% self-pay · Cancel any time

Ladies First is a women’s telehealth platform and does not provide medical services. All medical care is provided by our medical provider partner, an independent network of US-licensed medical providers; all medical decisions are made by a medical provider licensed in your state. Compounded preparations of semaglutide and tirzepatide are not FDA-approved for this specific formulation; they are dispensed by state-licensed compounding pharmacies operating under USP <795> and/or USP <797> standards. Individual results vary. Clinical trial data referenced applies to the FDA-approved branded products. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company; neither is affiliated with Ladies First. This page is general information, not medical advice. 100% self-pay.